Company Overview of Endo Pharmaceuticals Inc.
Endo Pharmaceuticals Inc. researches, develops, and sells pharmaceutical products. The company offers products for therapeutic areas that include pain management in the areas of postherpetic neuralgia, osteoarthritis, migraine, and chronic pain; urology and oncology for non-muscle invasive bladder and prostate cancer; and endocrinology for central precocious puberty and hypogonadism. It also provides clinical trials. The company was founded in 1994 and is headquartered in Malvern, Pennsylvania. Endo Pharmaceuticals Inc. operates as a subsidiary of Endo International plc.
1400 Atwater Drive
Malvern, PA 19355
Founded in 1994
Key Executives for Endo Pharmaceuticals Inc.
Chief Executive Officer, President and Director
Senior Vice President, Alliance Management
Compensation as of Fiscal Year 2014.
Endo Pharmaceuticals Inc. Key Developments
U.S. Food and Drug Administration accepts Endo Pharmaceuticals Inc.'s New Drug Application
Feb 23 15
Endo Pharmaceuticals Inc. and BioDelivery Sciences International Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the companies' BELBUCA(TM) (buprenorphine HCl) buccal film under development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. FDA has indicated a standard review designation for the NDA and therefore the action date is expected 10 months from the NDA submission (October 2015). Additionally, the FDA recently accepted BELBUCA as the proprietary name for (buprenorphine HCl) buccal film.
Endo Pharmaceuticals Inc. and BioDelivery Sciences International, Inc. Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
Dec 23 14
Endo Pharmaceuticals Inc. and BioDelivery Sciences International, Inc. announced that they have submitted a New Drug Application (NDA) for Buprenorphine HCl Buccal Film to the U.S. Food and Drug Administration (FDA). Buprenorphine HCl Buccal Film is under development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The drug uses BDSI's patented BioErodible MucoAdhesive (BEMA®) drug delivery technology to efficiently and conveniently deliver buprenorphine across the buccal mucosa (inside lining of the cheek). Buprenorphine, a Schedule III controlled substance, is a partial opioid agonist and a potent analgesic with a relatively long duration of action. Buprenorphine HCl Buccal Film is being developed and will be commercialized through a worldwide license and development agreement between Endo Pharmaceuticals and BDSI. The two pivotal phase 3 studies for demonstration of safety and efficacy were double-blind randomized, placebo-controlled, enriched-enrollment studies in patients with chronic lower back pain. One study (BUP-307) was conducted in opioid experienced subjects, and the second study (BUP-308) was conducted in subjects naïve to opioid therapy. Both studies met the primary efficacy endpoint of change from baseline to week 12 of mean daily pain intensity score from placebo (BUP- 307; p <0.00001; BUP 308; p= 0.001). Buprenorphine HCl Buccal Film was generally well tolerated demonstrating a low incidence of typical opioid like side effects.
Endo Pharmaceuticals and Impax Laboratories Face Second Proposed Class Action Lawsuit
Aug 22 14
Endo Pharmaceuticals and Impax Laboratories are facing a second proposed class action lawsuit over an alleged pay-to-delay deal that put off a generic launch of Endo's pain medication Opana ER. The Pennsylvania Employees Benefit Trust Fund filed a complaint against the brand and generics drugmakers in the U.S. District Court for the Northern District of Illinois, alleging that the delayed launch of Opana ER (oxymorphone hydrochloride) forced it to pay supracompetitive prices on the brand version for its members. The claims closely mirror ones made in a June lawsuit against Endo and Impax brought by the Rochester Drug Co-operative. Both lawsuits charge that in 2010, Endo settled patent infringement litigation against Impax's Paragraph IV ANDA against Opana ER with a deal to keep a generic version off the market for three more years. In exchange, the lawsuits allege, Endo agreed to pay Impax at least $112 million and as much as $142 million to hold off the generic launch. Endo also promised not to compete with Impax by launching its own generic, the complaints allege. Because Impax was the first to file against Opana, Endo was able to use its deal as a bottleneck against other ANDAs from generics makers Roxane, Actavis and Sandoz. Endo took full advantage of the delay, getting a revised, more crush-resistant version of the drug, Opana ER CRF, approved by the FDA. The drugmaker used the three year delay from its alleged 2010 deal with Impax until the 2013 generic launch to replace batches of Opana ER on the market with Opana ER CRF. That, in turn, further delayed generics competition by effectively neutralizing ANDAs that were not deemed by the FDA to be substitutable with the new version.
Similar Private Companies By Industry
Recent Private Companies Transactions